Amendment to License Agreement Between NewLink Genetics Corporation and Medical College of Georgia Research Institute
NewLink Genetics Corporation and the Medical College of Georgia Research Institute have amended their existing license agreement regarding the use of certain immuno-regulation technologies. This amendment adds a new technology to NewLink's licensed portfolio, effective once a specified license fee is paid. All related payments will be managed by the Medical College of Georgia Research Institute according to the original agreement's terms. The amendment is signed by authorized representatives of both parties and becomes part of the original license agreement.
Exhibit 10.49
LICENSE AGREEMENT AMENDMENT
Inasmuch as NewLink Genetics Corporation of Ames, Iowa, and the Medical College of Georgia Research Institute of Augusta Georgia, have a valid and existing License Agreement related to the use of Indoleamine-2,3-Dioxygenase and its inhibitors in Immuno-regulation [*] dated September 13, 2005;
and
Inasmuch as the parties agree that the License Agreement contains a provision (Section 4.1) for the acquisition of new, related Improvement Technologies by NewLink arising at MCGRI after the Agreement was signed
and
Inasmuch as the NewLink has reviewed a new Improvement Technology [*], and wishes to exercise its option to incorporate this technology into the existing License Agreement technology portfolio under its standard royalty terms and use conditions,
It is Agreed:
That the parties amend the License Agreement relative to its Exhibit A , such that MCG case [*] is to be included in the technology portfolio for development and commercialization by NewLink, effective the date that the License Fee of [*] is received at MCGRI. All Payments due to the [*] will be coordinated by MCGRI according to the terms stated in [*].
This present amendment shall hereby be considered part of the original License Agreement and is hereto agreed by representatives of both parties signing below.
MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE |
|
| NEWLINK GENETICS | ||
|
|
|
|
|
|
|
|
|
|
|
|
By | /s/Betty Aldridge |
|
| By: | /s/Nicholas N. Vahanian |
Name: | Betty Aldridge |
| Name: | Nicholas N. Vahanian | |
Title: | Executive Director |
| Title: | Chief Medical and Operations Officer | |
Date: | 2/13/07 |
|
| Date: 2/6/07 |